BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) is one of the 10 Stocks Dominating Today’s Market Action.
BioCryst grew its share prices by 7.10 percent on Thursday to close at $9.81 apiece as investors repositioned portfolios following rumors that it is set to be acquired by a large-cap US biopharmaceutical company.
The report first broke out on Monday from a website about deals and dealmakers, saying that a US-based pharmaceutical giant is setting its sights on BioCryst Pharmaceuticals Inc (NASDAQ:BCRX).
As of writing, BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) has yet to confirm or deny the said report.
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.
Last month, it announced strong earnings performance in 2025, having swung to a net income of $263.86 million last year from an $88.88 million net loss in 2024. Total revenues soared by 94 percent to $874.8 million from $450.7 million year-on-year, helped by the successful $243.3 million sale of its European Orladeyo business to Neopharmed Gentili. Orladeyo is a prescription oral medicine for preventing hereditary angioedema attacks in adults and children 12 years and older.
In the fourth quarter alone, BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) incurred a $245.8 million net income, reversing a $26.79 million net loss in the same period a year earlier. Total revenues more than tripled to $406.5 million from $131.5 million year-on-year.
While we acknowledge the potential of BCRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.
